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The glycoprotein IgM is the major antibody produced
in the primary immune response to antigens, circulating
in the serum both as a pentamer and a hexamer. Pen-
tameric IgM has a single J chain, which is absent in the
hexamer. The  (heavy) chain of IgM has five N-linked
glycosylation sites. Asn-171, Asn-332, and Asn-395 are
occupied by complex glycans, whereas Asn-402 and Asn-
563 are occupied by oligomannose glycans. The glycosy-
lation of human polyclonal IgM from serum has been
analyzed. IgM was found to contain 23.4% oligomannose
glycans GlcNAc2Man5–9, consistent with 100% occu-
pancy of Asn-402 and 17% occupancy of the variably
occupied site at Asn-563. Mannan-binding lectin (MBL)
is a member of the collectin family of proteins, which
bind to oligomannose and GlcNAc-terminating struc-
tures. A commercial affinity chromatography resin con-
taining immobilized MBL has been reported to be useful
for partial purification of mouse and also human IgM.
Human IgM glycoforms that bind to immobilized MBL
were isolated; these accounted for only 20% of total
serum IgM. Compared with total serum IgM, the MBL-
binding glycoforms contained 97% more GlcNAc-termi-
nating structures and 8% more oligomannose struc-
tures. A glycosylated model of pentameric IgM was
constructed, and from this model, it became evident that
IgM has two distinct faces, only one of which can bind to
antigen, as the J chain projects from the non-antigen-
binding face. Antigen-bound IgM does not bind to MBL,
as the target glycans appear to become inaccessible
once IgM has bound antigen. Antigen-bound IgM pen-
tamers therefore do not activate complement via the
lectin pathway, but MBL might have a role in the clear-
ance of aggregated IgM.
The glycoprotein IgM is the major antibody produced in the
primary immune response to foreign antigens. It exists both as
part of the B cell antigen receptor on the surface of B cells and
as a secreted glycoprotein. Human secreted IgM is a multim-
eric molecule consisting of five (pentameric) (Fig. 1) or six
(hexameric) 190-kDa subunits, each of which consists of two
heavy () and two light chains. Pentameric IgM has also a
single 20-kDa J chain, which is absent in hexameric IgM (1).
The  (heavy) chains consist of five Ig domains termed V,
C1, C2, C3, and C4. Interchain disulfide bridges occur in
the C2, C3, and C4/tail domains at Cys-337, Cys-414, and
Cys-575, respectively. Light chains are attached to Cys-136 in
the C1 domain. The polymerization of IgM requires Cys-575
(2), located on the 18-residue tail piece, at the C terminus of
each C4 domain. In contrast to the Ig domains, the tail piece
has no defined secondary or tertiary structure (3), but is re-
quired for the polymerization of monomeric IgM (4). The J
chain is attached via Cys-14 and Cys-68 to the penultimate
amino acid of two  chains in pentameric IgM (Cys-575) (5–7).
In the absence of a J chain during polymerization, cells secrete
solely hexameric IgM (8). The J chain also binds to the poly-Ig
receptor, which mediates epithelial transcytosis (9).
Human secreted IgM has five N-linked glycosylation sites on
each  chain, located at Asn-171, Asn-332, Asn-395, Asn-402,
and Asn-563. The J chain contains a single N-linked glycosy-
lation site at Asn-48. The light chains ( or ) contain no
conserved N-linked glycosylation sites. Glycosylation is vital to
IgM secretion and B cell surface presentation (10). Oligoman-
nose structures have been shown to occupy two N-linked sites
on IgM at Asn-402 and Asn-563 (11, 12). These oligosaccha-
rides may present a target for serum mannan-binding lectin
(MBL).1
MBL, also known as mannan/mannose-binding protein, is a
member of the collectin family of proteins (13). MBL is synthe-
sized in the liver and secreted into the bloodstream. It binds
calcium-dependently to sugars that have hydroxyl groups on
C-3 and C-4 orientated in the equatorial plane of the pyranose
ring (14). This gives MBL affinity for mannose, fucose, and
GlcNAc (15) present on the surfaces of microorganisms, includ-
ing bacteria, viruses, and fungi (16), but not generally for
human glycoprotein glycans, the structures of which usually
terminate in galactose or sialic acid. It binds to sugar residues
via the carbohydrate recognition domain (lectin) heads. The
affinity of a single carbohydrate recognition domain for carbo-
hydrate is very weak (103 M) (17), but multiple carbohydrate
recognition domain binding leads to much greater avidity. The
levels of MBL in human serum vary greatly between individ-
uals (15), from 50 ng/ml to 10 g/ml.
MBL has a structure and function similar to those of the
complement protein C1q and participates in the host defense
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response through two major pathways. First, it acts directly as
an opsonin, promoting phagocytosis of foreign material to
which it has bound. Second, it triggers the lectin pathway of
complement activation (18, 19). MBL circulates bound to MBL-
associated serine proteases (MASPs) (19). Three MASPs have
been characterized to date: MASP-1 and MASP-2 (20, 21) and
MASP-3 (22). MASP-2 has been shown to cleave complement
components C4 and C2, resulting in the formation of the C3
convertase C4b2a. The biological roles of MASP-1 and MASP-3
are unknown, although MASP-1 is known to cleave fibrinogen
and activate Factor XIII (19).
Glycoproteins, including the immunoglobulins, consist of a
collection of glycosylated variants (glycoforms) in which a sin-
gle amino acid sequence is diversified by the variable process-
ing of glycans at each of the glycosylation sites. Some of these
subpopulations may have glycans that are ligands for MBL.
This has been demonstrated for IgG. MBL has been shown to
bind agalactosyl glycoforms of IgG (known as IgG-G0) in which
the single Asn-297 N-linked site in the IgG  chain is occupied
by glycans that have terminal GlcNAc residues (23). IgG-G0
accounts for 35% of normal serum IgG (24). MBL also binds
polymeric forms of serum IgA (25), but the IgA glycans to which
MBL binds have not been identified.
There are conflicting reports about whether MBL interacts
with IgM. Immobilized human myeloma IgM does not bind to
human MBL (26), although mouse IgM and, to a lesser extent,
human and bovine IgM can bind to immobilized rabbit MBL
(27). Rat MBL has also been reported to bind human IgM (28).
The oligomannose structures that occupy Asn-402 and Asn-563
are potential ligands for MBL binding (28).
Electron microscopy studies have shown that a considerable
conformational change occurs in the IgM pentamer when it has
bound to antigen. This might allow IgM to expose its oligo-
mannose glycans upon antigen binding, providing a potential
mechanism of clearance of IgM after its initial recognition via
an MBL-dependent pathway (3). IgM interacts efficiently with
the complement system and constitutes a first line of defense
against infection. However, hexameric IgM is 20 times more
efficient at activating complement compared with pentameric
IgM (1, 29, 30). The complement activation by IgM is attributed
to C1q binding. The charged residues Asp-417, Glu-418, and
His-420 in the C3 domain of IgM have been proposed as the
binding site for C1q on IgM (31).
Here, we present the first comprehensive report of normal
human serum IgM glycosylation and identify glycoforms of
human serum IgM that do bind to MBL. Using molecular
modeling, we have constructed a complete structure of glyco-
sylated pentameric IgM and have assessed the accessibility of
the identified oligomannose structures as binding targets for
MBL.
EXPERIMENTAL PROCEDURES
Antibodies and Antisera—Rabbit antiserum against recombinant
MBL was adsorbed to remove anti-mannan antibodies and rheumatoid
factors as described previously (32).
Protein Concentration—Protein samples (25 g in any volume) were
concentrated for general SDS-PAGE analysis by incubation with slow
rotation at room temperature for 30 min with a 5-l packed volume of
StrataCleanTM resin (Stratagene, Zuidoost, The Netherlands). The
samples were then spun at 13,000 rpm for 1 min, and the supernatant
was discarded. The resin was resuspended in 20 l of SDS-PAGE
sample buffer (200 mM Tris, 8 M urea, 2% SDS, and 1 mM EDTA, pH 8)
and loaded onto the gel.
IgM was concentrated by chloroform/methanol precipitation adapted
from the procedure described previously (33). To 100 l of IgM sample
(in phosphate-buffered saline (PBS) and 0.5 mM EDTA) was added 400
l of methanol. This was vortexed and spun at 13,000 rpm for 30 s, and
100 l of chloroform was added, vortexed, and spun again. To this was
added 300 l of water, followed by vortexing and spinning. There was a
phase separation; the upper phase was removed and discarded; and 300
l of methanol was added and vortexed. The precipitated IgM was
pelleted by spinning at 13,000 rpm for 3 min. The supernatant was
removed and discarded, and the pellet was dried in a vacuum centrifuge
(Savant SpeedVac®, Thermo LifeSciences, Basingstoke, UK) for 30
min. This pellet was dissolved in 30 l of sample buffer for SDS-PAGE
analysis.
Large-scale IgM Purification from Human Serum—The purification
method was adapted from that of Johnstone and Thorpe (34). 1 liter of
citrated pooled normal human plasma (HDS Supplies, High Wycombe,
UK) was made 20 mM CaCl2 and left overnight at 4 °C to clot. The clot
was filtered through muslin. IgM was precipitated from the serum at
low salt by dialysis against 3  10 liters of 2 mM sodium phosphate, pH
6.0. The sample was centrifuged at 11,000  g for 20 min at 4 °C; the
supernatant was discarded; and the pellet washed twice by resuspen-
sion in 100 ml of 2 mM sodium phosphate, pH 6.0, at 4 °C. The pellet was
redissolved in 100 ml of Tris-buffered saline (10 mM Tris-HCl, 150 mM
NaCl, and 0.5 mM EDTA, pH 7.3) at room temperature and centrifuged
at 11,000  g for 20 min at room temperature to remove undissolved
material. A 50-ml sample was then applied to a Sepharose 4B gel
filtration column (2.6  100 cm; Amersham Biosciences AB, Uppsala,
Sweden) pre-equilibrated with Tris-buffered saline, pH 7.4, at 4 °C, and
the fractions judged to contain IgM by SDS-PAGE analysis were pooled.
The sample was run through 215 ml of Matrex Blue B resin (3.2  30
cm; Amicon Inc., Beverly, MA) pre-equilibrated with Tris-buffered sa-
line, pH 7.4. The flow-through fractions containing IgM were collected
and pooled. IgM still contained small amounts of IgG and IgA identified
by SDS-PAGE analysis and direct enzyme-linked immunosorbent assay
(ELISA) using alkaline phosphatase-conjugated goat anti-human IgG
( chain-specific; A3187, Sigma, Poole, UK) and alkaline phosphatase-
conjugated goat anti-human IgA ( chain-specific; Sigma). IgG was
removed using a 5-ml HiTrap-protein G column (Amersham Biosciences
AB), and IgA was removed by passage through an anti-IgA ( chain-
specific)-Sepharose column (A2691, Sigma). The final IgM was judged
by SDS-PAGE analysis to be 95% pure and was dialyzed against
FIG. 1. Diagrammatic structure of pentameric IgM and IgG1.
The diagrammatic representation of pentameric IgM and IgG1 shows
the variable and constant heavy chain (VH and CH, respectively) and
light chain (VL and CL, respectively) domains. The diagram also shows
the Fab and Fc domains. The locations of the asparagines to which
N-linked glycans are attached are marked. The J chain is also shown on
the IgM structure.
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Dulbecco’s PBS (8.2 mM Na2HPO4, 1.5 mM KH2PO4, 139 mM NaCl, and
3 mM KCl, pH 7.4; Oxoid Ltd., Hampshire, UK) containing 0.5 mM
EDTA.
Small-scale IgM Purification from Human Serum Using an Immu-
noPure® IgM Purification Kit—The ImmunoPure® IgM purification kit
was purchased from Pierce. The column was rabbit MBL-conjugated to
a 4% beaded agarose support (5 ml), sold as a kit for purification of
mouse IgM from ascites fluid. The column was run using human serum
according to the directions of the manufacturer. The column was pre-
washed with 5 ml of ImmunoPure® MBP (mannan-binding protein)
column preparation buffer (Tris, sodium chloride, sodium azide, and
EDTA, pH 7.4) at room temperature and then equilibrated with 20 ml
of ImmunoPure® IgM binding buffer (Tris, sodium chloride, calcium
chloride, and sodium azide, pH 7.4) at 4 °C. Human serum (500 l) from
citrated plasma as described above diluted 1:1 with ImmunoPure® IgM
binding buffer was applied to the column at 4 °C and allowed to enter
the resin completely. An additional 500 l of ImmunoPure® IgM bind-
ing buffer was added and also allowed to enter the resin. The column
was then incubated at 4 °C for 30 min and washed with 42 ml of
ImmunoPure® IgM binding buffer. Bound protein was eluted at room
temperature with 8 ml of ImmunoPure® IgM elution buffer (Tris,
sodium chloride, sodium azide, and EDTA, pH 7.4).
The bound proteins were analyzed by SDS-PAGE and found to be a
complex mixture containing 5% IgM. The material in the buffer as
described above was run on a 10-ml anti-human IgM-agarose column
(Medical Research Council Immunochemistry Unit), and the column
was washed with 10 mM Hepes, 1 M NaCl, and 0.5 mM EDTA, pH 7.4.
IgM was eluted from the column with 3 M MgCl2, and 1-ml fractions
were collected. The fractions containing protein (detected by reading
the absorbance at 280 nm) were pooled and dialyzed against 10 mM
Hepes, 1 M NaCl, and 0.5 mM EDTA, pH 7.4. The material was passed
through a 1-ml HiTrap-protein G column (Amersham Biosciences AB)
to remove IgG. IgM was judged to be 95% pure by SDS-PAGE
analysis.
Preparation of 2,4,6-Trinitrophenyl (TNP)-conjugated Bovine Serum
Albumin (BSA) and TNP-BSA-Sepharose—TNP-BSA was prepared by
mixing 10 ml of 1% BSA in PBS and 0.5 mM EDTA with 2 ml of 5% (w/v)
picrylsulfonic acid solution (P2297, Sigma). The pH was monitored to
keep the mixture neutral to prevent BSA precipitation, and the mixture
was left for 4 h at room temperature. TNP-BSA was then dialyzed
exhaustively at 4 °C against PBS and 0.5 mM EDTA. TNP-BSA-Sepha-
rose was prepared with 2 g of cyanogen bromide-activated Sepharose
4B (Amersham Biosciences AB) according to the manufacturer’s in-
structions. Excess binding sites on the resin were blocked with 100 mM
ethanolamine HCl and 150 mM NaCl, pH 8.5, and mixed by rotating for
2 h at room temperature. The resin was then equilibrated with PBS and
0.5 mM EDTA. The final resin contained 5 mg of TNP-BSA/ml of packed
Sepharose.
Purification and Arthrobacter ureafaciens Sialidase (ABS)/Bovine
Testis -Galactosidase (BTG) Treatment of Anti-TNP-BSA IgM from
Human Serum—IgM was low salt-precipitated from 1 liter of pooled
human serum (citrated pooled normal human plasma from HDS Sup-
plies) and redissolved as described above. The IgM solution in Tris-
buffered saline was spun at 60,000 rpm for 45 min to diminish lipid
contamination, which formed as a layer at the meniscus. The material
was passed through 5 ml of TNP-BSA-Sepharose in PBS and 0.5 mM
EDTA. Bound material was eluted using 0.2 M glycine HCl, pH 2.2, and
dialyzed against PBS and 0.5 mM EDTA. The major proteins eluted
were IgM, IgG, Factor H, and IgA (identified by SDS-PAGE and mass
spectrometry) (data not shown). IgG and IgA were removed as described
above. Factor H was removed from the preparation by running the
material through a 10-ml MRC OX23-Sepharose column (35). The final
preparation was judged to be 95% pure IgM by SDS-PAGE analysis.
The preparation was then treated with the exoglycosidases ABS (EC
3.2.1.18) at 3 milliunits/ml and BTG (EC 3.2.1.23) at 1 unit/ml to cleave
the complex glycans on IgM to a terminal GlcNAc (a residue that would
bind MBL). anti-TNP-BSA IgM (4.8 g) in 4 ml of PBS was incubated
with 30 microunits of ABS and 20 milliunits of BTG for 16 h at 37 °C
and for several days at 4 °C.
IgM Quantification by ELISA—The wells of an ELISA plate (Maxi-
sorp, Nunc, Roskilde, Denmark) were coated with 100 l of 10 g/ml
goat anti-human IgM ( chain-specific; H15000, Caltag Laboratories,
Burlingame, CA) in 0.1 M NaHCO2, pH 9.5. The wells were incubated
overnight at 4 °C; blocked with 400 l of PBS and 0.1% Tween 20 for 2 h
at room temperature; and washed three times with 200 l of PBS, 0.1%
Tween 20, and 0.5 mM EDTA. IgM preparations were serially diluted in
PBS and 0.1% Tween 20. IgM from the large-scale preparation was
quantified from absorbance readings at 280 nm (extinction coefficient of
1.18 for 1 mg/ml) (34) and incubated, as a standard, for 1 h at room
temperature. The wells were washed three times with PBS and 0.1%
Tween 20, incubated with alkaline phosphatase-conjugated goat anti-
human IgM ( chain-specific; 1:2000 dilution; A3437, Sigma) for 1 h at
room temperature, and washed again. 100 l of p-nitrophenyl phos-
phate substrate (N1891, Sigma) was added; and the absorbance was
read at 405 nm after 30 min.
SDS-PAGE Separation of the J Chain and Western Blotting for the
J Chain—The J chain has an apparent molecular mass similar to that
of the Ig light chain on SDS-polyacrylamide gel. To separate these
proteins for analysis ofN-linked glycans, 20 g of pooled normal human
IgM was run on a Tricine-10–20% acrylamide gradient precast gel
(Invitrogen, Paisley, UK) for 70 min at 150 V in 1 NuPAGE® MES
SDS running buffer (NP0002, Invitrogen). These gels were stained with
SimplyBlue SafeStain (LC3065, Invitrogen) for 30 min and destained in
water to visualize the bands.
Western blotting was performed to locate the position of the J chain
on the gel. An unstained gel was soaked in Western transfer buffer (25
mM Tris, 0.2 M glycine, and 20% (v/v) methanol) for 10 min. A transfer
membrane (Millipore Corp., Bedford, MA) was prepared by soaking for
10 s in methanol, for 15 min in water, and for 15 min in transfer buffer.
The semidry blot was run at 1.2 mA/cm2 for 1 h at room temperature.
The membrane was blocked with 1% (w/v) milk solution for 2 h at room
temperature, washed three times for 5 min each with PBS and 0.1%
Tween 20, and then incubated for 1 h with 0.5 g/ml mouse anti-human
J chain antibody (MCA693, Serotec, Oxford, UK) in the wash buffer.
The membrane was washed three times, incubated with alkaline phos-
phatase-conjugated goat anti-mouse IgG ( chain-specific; 1:2000 dilu-
tion; A3438, Sigma) for 1 h at room temperature, washed three times,
and visualized using Sigma FASTTM 5-bromo-4-chloro-3-indolyl phos-
phate/nitro blue tetrazolium tablets (B5655, Sigma). This identified the
position of the J chain that was separated the light chain.
Removal of N-Linked Glycans for Analysis—Human IgM (20 g)
prepared by the large-scale method or by small-scale method using an
ImmunoPure® IgM purification kit was run on SDS-polyacrylamide
gel, followed by in-gel N-linked glycan release using peptide N-gly-
canase F (1000 units/ml; glycopeptidase, EC 3.5.1.52) as described
previously (36, 37).
2-Aminobenzamide (2-AB) Labeling—Released glycans were labeled
by reductive amination with the fluorophore 2-AB (38) using a
LudgerTagTM 2-AB glycan labeling kit (Ludger Ltd., Oxford, UK).
Normal Phase (NP) HPLC and Weak Anion Exchange HPLC—La-
beled glycans were separated by NP-HPLC (39) and weak anion ex-
change HPLC (40). Glycan profiles from NP-HPLC were calibrated
against a dextran ladder prepared from hydrolyzed and 2-AB-labeled
glucose oligomers (39). Glycans were assigned glucose units, and glycan
structure/composition was predicted by reference to a glycan data base
using the program PeakTime.2
Exoglycosidase Digestions—Exoglycosidases were used to confirm
the structures of glycans present in the preparations in conjunction
with NP-HPLC (37). Enzymes were used at the concentrations recom-
mended by the manufacturers, and digestions were carried out using 50
mM sodium acetate buffer, pH 5.5, for 16 h at 37 °C. The following
enzymes were supplied by Glyko Inc. (Upper Heyford, UK): ABS (1–2
units/ml), almond meal -fucosidase (3 milliunits/ml; EC 3.2.1.51), BTG
(1 unit/ml), jack bean -mannosidase (100 milliunits/ml; EC 3.2.1.24),
Streptococcus pneumoniae -N-acetylhexosaminidase (120 units/ml; EC
3.2.1.52), and bovine kidney fucosidase (100 units/ml; EC 3.1.1.51).
Europa Bioproducts (Cambridge, UK) supplied S. penumoniae recom-
binant sialidase expressed in E. coli (1 unit/ml; Nanl; EC 3.2.1.18). The
glucosidase II was prepared in the Glycobiology Institute.
Mass Spectrometry—Non-2-AB-labeled N-linked glycans were ana-
lyzed by MALDI-TOF mass spectrometry from 2,5-dihydroxybenzoic
acid (41).
Calculations of the Number of GlcNAc-terminating and Hybrid Gly-
cans/IgM Pentamer—The average number of GlcNAc-terminating and
hybrid structures/IgM pentamer was calculated to identify the number
of potential MBL ligands present on each IgM pentamer. For example,
taking values from Table III, pooled human IgM had a total of 7.5%
structures that could potentially act as ligands for MBL occupying
Asn-171, Asn-332, and Asn-395, with a probability of 0.075 at each site.
There are 10  chains/IgM pentamer, each with the three N-linked
glycosylation sites (Asn-171, Asn-332, and Asn-395) bearing complex
sugars; therefore, 2.3 (i.e. 30  0.075) GlcNAc-terminating/hybrid gly-
cans are present, on average, on each IgM pentamer.
2 E. Hart, R. A. Dwek, and P. M. Rudd, unpublished data.
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MBL Purification—The purification procedure has been described
previously (32, 42). Trace contaminants (IgG and IgM) were identified
by SDS-PAGE analysis and direct ELISA using alkaline phosphatase-
conjugated goat anti-human IgG ( chain-specific) and alkaline phos-
phatase-conjugated goat anti-human IgM ( chain-specific). The prep-
aration was passed through a 1-ml HiTrap-protein G column and then
10 ml of anti-human IgM-agarose. The protein was dialyzed against 10
mM Hepes, 149 mM NaCl, and 5 mM CaCl2, pH 7.4; concentrated by
binding to 500 l of mannose-agarose (M6400, Sigma); and eluted with
10 mM Hepes, 140 mM NaCl, and 5 mM EDTA, pH 7.4. The sample was
judged to be 95% pure by SDS-PAGE analysis. The concentration of
MBL was calculated using a mannan capture MBL ELISA (32).
Assay for MBL Binding to IgM Preparations—The procedure for
ELISA was that described by Arnold et al. (32). The wells of an ELISA
plate were coated with 100 l of 50 g/ml TNP-BSA and blocked by the
same method described for the IgM ELISA. After blocking, the wells
were incubated with 100 l of ABS- and BTG-treated anti-TNP-BSA
IgM (120 ng/well) in PBS (previously shown by ELISA to saturate the
TNP-BSA (data not shown)). In other wells, ABS- and BTG-treated
anti-TNP-BSA IgM (120 ng/well), IgM from the large-scale bulk-puri-
fied serum IgM (120 ng/well), or IgM purified from the MBL-conjugated
resin (120 ng/well) was coated directly onto the wells. Mannan (M7504,
Sigma) and BSA were used for coating as positive and negative controls,
respectively, at 50 g/ml. An additional negative control of the enzyme
digestion mixture of ABS and BTG was bound directly to the well
without anti-TNP-BSA IgM. MBL binding was assessed using a 1:700
dilution of rabbit anti-human polyclonal MBL antiserum and a 1:2000
dilution of alkaline phosphatase-conjugated anti-rabbit monoclonal IgG
( chain-specific, RG-96; A2556, Sigma) as described by Arnold et al.
(32) and developed with the substrate 1 mM 4-methylumbelliferyl phos-
phate (474431, Calbiochem) in 5 mM CHES and 1 mM MgCl2, pH 9.8,
and the fluorescence was measured at ex  355 nm and em  460 nm
after 1 h.
Molecular Modeling—Sequence alignment was performed using
Align (43) on the equivalent domains of IgG and IgE (Swiss-Prot acces-
sion numbers P01857 and P01854, respectively). Molecular modeling
was performed on a Silicon Graphics Fuel workstation using Insight II
and Discover software (Accelrys Software Inc., San Diego, CA). Crystal
structures used as the basis for modeling were obtained from the
Protein Data Bank (44). The monomeric IgM molecular models for the
Fc and hinge domains were based on the crystal structure of the IgE Fc
domain (45), and the Fab domains were based on the crystal structure
of IgG (46). The J chain was based on the J chain from the molecular
model of secretory IgA (47). N-Glycan structures were generated using
the data base of glycosidic linkage conformations (48, 49) and in vacuo
energy minimization to relieve unfavorable steric interactions. The
Asn-GlcNAc linkage conformations were based on the observed range of
crystallographic values (50). The details of the construction of the IgM
pentamer from the monomer units will be published elsewhere.3
RESULTS
IgM Quantification from Purified IgM Preparations—The
pooled serum for the IgM purifications contained 1774 g of
IgM/ml of serum. Large-scale IgM bulk-purified from 1 liter of
pooled serum (Fig. 2a) gave a final yield of 78 g of IgM/ml of
serum (4% of total IgM), which was quantified by reading the
absorbance at 280 nm.
The MBL column from the ImmunoPure® IgM purification
kit had a binding capacity of 180 g of human IgM. Repeated
passage of 0.5 ml of serum over the column indicated that200
g of IgM could be extracted from 0.5 ml of serum (22% of
total IgM). Bound IgM that eluted with EDTA was impure,
representing5% of the eluted proteins. When further purified
using a protein G resin to remove IgG and an anti-IgM resin to
select IgM (Fig. 2b), the final yield of IgM was 68 g from 0.5 ml
of serum (i.e. 8% of total IgM). Anti-TNP-BSA IgM was derived
from 1 liter of pooled human serum (Fig. 2c) with a yield of
0.042 g of anti-TNP-BSA IgM/ml of serum.
N-Linked Glycans of Pooled Human Serum IgM—Glycans
were released from the  chain of IgM prepared by large-scale
purification (Fig. 2a). The released glycans were analyzed by
MALDI-TOF mass spectrometry and NP-HPLC of the 2-AB-
labeled material (Fig. 3). Structures of the glycans were as-
signed based on their glucose units, shifts in glucose units with
enzyme digest arrays, and molecular masses (Table I). Sialy-
lated glycans could be digested with ABS, but not with Nan1,
indicating that all sialic acid residues are 2,6 (not 2,3)-linked
to galactose. Weak anion exchange HPLC and enzyme diges-
tions showed the presence of neutral and mono- and disialy-
lated structures as well as oligomannose glycans.
N-Linked Glycosylation of Asn-402 and Asn-563—Normal
human serum IgM contains GlcNAc2Man5–9 structures
(Table I), with two predominant oligomannose structures,
GlcNAc2Man6 and GlcNAc2Man8, which account for 9.5 and
4.1% of the total glycan pool, respectively. This is consistent
with previous myeloma IgM glycan analysis (3, 11–12). Assum-
ing full occupancy of all five glycosylation sites and that Asn-
402 and Asn-563 contain only oligomannose glycans, then oli-
gomannose glycans should compose 40% of the total glycan
pool. In fact, oligomannose glycans composed only 23.4% of the
N-linked glycan pool in this pooled normal human serum IgM.
The Asn-402 site in the IgM Fc domain is homologous to the
Asn-297N-linked glycosylation site in IgG, Asn-354 in IgD, and
Asn-394 in IgE, which are all fully occupied (32). Asn-563 has
been shown to have a 75% occupancy in human-mouse hybri-
doma human IgM (51) and a 44% occupancy in murine IgM
(52). Assuming 100% occupancy of Asn-402, 23.4% oligoman-
nose glycans would account for 17% occupancy at Asn-563.
IgE and IgM possess a CH2 hinge domain, replacing the
flexible hinge region in IgG, IgD, and IgA. The crystal structure
of IgE (45) showed that the CH2 hinge domain adopts an
asymmetrically bent conformation relative to the Fc domain.
The relatively unprocessed glycans on the IgE Fc domain Asn-
394 N-linked glycosylation site remain predominantly
GlcNAc2Man5 and GlcNAc2Man6 structures. This can be ex-
plained by the CH2 hinge domain blocking access to the gly-
cans and thus preventing processing. The CH2 domain must
then “flip” between two bent quaternary conformations to block
access to the two Asn-394 glycans on opposite sides of the Fc3 J. N. Arnold, unpublished data.
FIG. 2. SDS-PAGE analysis of reduced and alkylated IgM. Sam-
ples were run on 4–15% BisTris gels (Invitrogen) alongside 7 l of
MultiMark protein ladder (Invitrogen). a, 20 g of the purified IgM
preparation from normal human serum. b, 20 g of purified IgM eluted
from the MBL resin after the additional purification steps with anti-
human IgM-agarose and HiTrap-protein G. Bands were excised and
analyzed. c, purification of anti-TNP-BSA IgM. Lane I, material eluted
from TNP-BSA-Sepharose; lane II, material after the HiTrap-protein G
resin; lane III, material after the anti-human IgA resin; lane IV, final
material after the OX23 resin. The presence of IgMwas confirmed using
a direct ELISA with alkaline phosphatase-conjugated goat anti-human
IgM ( chain-specific). Ig L Chain, Ig light chain.
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domain (32). The extent of processing at the Asn-402 site in
IgM is similar to that at Asn-394 in IgE. The CH2 hinge
domain in IgM may also adopt this asymmetrically bent con-
formation and thus lead to similar processing of the glycans
occupying Asn-402 as observed in IgE.
N-Linked Glycosylation of Asn-171, Asn-332, and Asn-395—
The non-oligomannose complex structures accounted for 76.6%
of the released glycan pool and must be found chiefly at Asn-
171, Asn-332, and Asn-395. Monosialylated structures ac-
counted for 70.9% and disialylated structures for 9.7% of the
complex glycan pool (Table I). Bisected structures (those con-
taining “B” in Table I) accounted for 52.5% of the complex
glycan pool. Fukuta et al. (53) found comparable quantities of
bisected glycans in transformed B cell line human IgM (named
IgM-12; 49.9, 67.8, and 81.3% at each site, respectively); how-
ever, human-mouse hybridoma IgM3-4 has significantly fewer
bisected structures (3.7, 8.7, and 15.3% at each site, respec-
tively). In this study, core-fucosylated structures (“Fc” in Table
I) accounted for 84.5% of the complex glycan pool of normal
human serum IgM, comparable with the results for both my-
elomas IgM3-4 and IgM-12 (53).
In heterohybridoma human IgM (54), hybrid structures
GlcNAc2A1Man4G1 and GlcNAc2A1Man4G1S1 (see the legend
to Fig. 3 for explanation of glycan nomenclature) have one arm
terminating in mannose, occur at Asn-171, and account for
42.5% of the glycans at that site. However, the human serum
IgM studied here contained a significantly lower percentage of
hybrid structures (0.9% of GlcNAc2A1Man4G1 and 2.5% of
GlcNAc2A1Man4G1S1) (Fig. 3).
N-Linked Glycans of the Pooled IgM J Chain—The J chain of
IgM has a single N-linked glycosylation site. The N-linked
glycans were released from the pooled serum IgM J chain,
2-AB-labeled, and analyzed by NP-HPLC before and after di-
gestion with ABS and with ABS and BTG (Fig. 4 and Table II).
Structural assignments were made based on glucose units and
exoglycosidase digestions. The profile shows the presence of
neutral and mono- and disialylated structures (Fig. 4). The
normal human IgM J chain was found to be occupied predom-
inantly by GlcNAc2A2G2S1 structures, accounting for 44% of
the glycan pool. This structure is also the most abundant gly-
can in the secretory IgA J chain (45). Royle et al. (47) also
identified a comparable content of FcGlcNAc2A2G2S1 (13.6%),
GlcNAc2A2G2S2 (13.8%), and FcGlcNAc2A2G2S2 (17%). Here,
we report 15, 17, and 8% of these three structures, respectively,
on the IgM J chain. Normal human serum IgM J chain glycans
were found to be 25.7% core-fucosylated and to have no bisect-
ing GlcNAc residues.
Comparison of the Glycans in Pooled Serum IgM and Those
in IgM Eluted from the MBL Resin—TheN-linked glycans were
released from the purified IgM  chain eluted from the MBL-
conjugated resin (Fig. 2b) and subjected to NP-HPLC, and
FIG. 3. NP-HPLC exoglycosidase digestion profile of the gly-
can pool from IgM. 2-AB-labeled N-linked glycans were digested by
exoglycosidases and analyzed by NP-HPLC. All N-glycans have two
core GlcNAc residues. Fc, core fucose linked 1–6 to the inner GlcNAc
residue; Mann, number (n) of mannose residues on core GlcNAc resi-
dues: An, number of antennae on the trimannosyl core (A2  bianten-
nary); B, bisecting GlcNAc linked 1–4 to the inner mannose; Gn,
number of galactose residues on the antennae; Sn, number of sialic acids
on the antennae. Percentage areas and glucose units (GU) are shown in
Table I. The exoglycosidases used were ABS (removes sialic acid), BTG
(removes galactose), bovine kidney fucosidase (BKF; removes core fu-
cose), and N-acetyl--glucosaminidase (GuH; removes terminal
GlcNAc).
TABLE I
Pooled normal IgM  chain N-linked glycans
GU, glucose units.
Structurea GU Molecularmassb
Compositionc Glycan
poolHex HexNAc Fuc Neu5Ac
Da %
GlcNAc2A1 4.90 ND 3 3 0 0 0.9
GlcNAc2A2 5.03 1339.4 3 4 0 0 0.4
GlcNAc2A2B 5.58 ND 3 5 0 0 1.3
FcGlcNAc2A2 5.71 1485.5 3 4 1 0 0.2
GlcNAc2A3 5.71 ND 3 5 0 0 0.2
FcGlcNAc2A2B 5.90 ND 3 5 1 0 0.2
GlcNAc2Man5 6.17 1257.4 5 2 0 0 5.6
GlcNAc2A1Man4G1 6.33 1460.6 5 3 0 0 0.7
GlcNAc2A2G1 6.60 1501.5 4 4 0 0 1.1
GlcNAc2A2BG1 6.60 1704.6 4 5 0 0 0.7
FcGlcNAc2A2G1 6.87 1647.6 4 4 1 0 0.4
FcGlcNAc2A2BG1 6.87 1850.6 4 5 1 0 0.6
GlcNAc2A3G1 6.87 1704.6 4 5 0 0 2.1
GlcNAc2Man6 7.06 1419.4 6 2 0 0 9.5
GlcNAc2A2G2 7.06 1663.6 5 4 0 0 ND
GlcNAc2A2BG2 7.30 1886.7 5 5 0 0 ND
GlcNAc2A1Man4G1S1 7.30 DS 5 3 0 1 1.9
FcGlcNAc2A2G2 7.58 1809.6 5 4 1 0 1.1GlcNAc2A3G2 7.58 1866.7 5 5 0 0
FcGlcNAc2A2G1S1 7.58 DS 4 4 1 1 1.8
FcGlcNAc2A2BG2 7.66 2012.8 5 5 1 0 4.2
FcGlcNAc2A2BG1S1 7.66 DS 4 5 1 1 1.1
FcGlcNAc2A3G2 7.76 2012.8 5 5 1 0 1.0
GlcNAc2Man7 7.92 1581.6 7 2 0 0 3.2
GlcNAc2A2G2S1 7.92 DS 5 4 0 1 1.7
GlcNAc2A2BG2S1 8.22 DS 5 5 0 1 1.1
FcGlcNAc2A2G2S1 8.33 DS 5 4 1 1 18.7
FcGlcNAc2A2BG2S1 8.52 2325.8 5 5 1 1 26.2
GlcNAc2Man8 8.81 1743.6 8 2 0 0 4.1
FcGlcNAc2A2G2S2 9.11 DS 5 4 1 2 2.6
FcGlcNAc2A3G2S1 9.11 2325.8 5 5 1 1 1.9
FcGlcNAc2A2BG2S2 9.19 DS 5 5 1 2 4.8
GlcNAc2Man9 9.51 1905.7 9 2 0 0 1.0
a Glycan nomenclature is explained in the legend to Fig. 3.
b Molecular masses are of unlabeled glycans, detected as [M  Na]
by MALDI mass spectrometry. All masses were within 0.2 mass units of
calculated values. DS, desialylated mass detected. Sialylated structures
during MALDI lost most sialic acid residues. ND, not detected by
NP-HPLC.
c Compositions were deduced from mass values.
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glycan structures were assigned to the peaks. The same glycan
structures were identified in both IgM preparations (Fig. 5),
but there was a 97.3% increase in GlcNAc-terminating and
hybrid structures (Table III, part A) in IgM eluted from the
MBL resin. These structures occupied Asn-171, Asn-332, and
Asn-395, as Asn-402 and Asn-563 are occupied only by oligom-
annose structures. There was also a 7.8% increase in overall
oligomannose structures (Table III, part B) from the total gly-
can pool, mostly by an increase in GlcNAc2Man8 structures.
MBL Binding Studies—The binding of MBL to the purified
IgM preparations was assessed using microtiter plates that
had been coated with antigen-bound IgM or directly immobi-
lized IgM (Fig. 6). Assays were carried out in triplicate or over
6 wells with additional negative EDTA controls. Only slight
binding to antigen-bound IgM (ABS- and BTG-treated anti-
TNP-BSA IgM) and bulk serum IgM was observed. However,
directly immobilized IgM eluted from the MBL resin, and di-
rectly immobilized ABS- and BTG-treated anti-TNP-BSA IgM
showed a much higher level of MBL binding. The ABS and BTG
enzyme mixture alone showed no MBL binding.
DISCUSSION
N-Linked Glycosylation of Normal Human Serum IgM—IgM
contains a range of N-linked glycans (Table I) terminating
predominantly in sialic acid and galactose, but also in mannose
and GlcNAc (Fig. 7). By reference to previous reports (3, 6, 12),
we conclude that oligomannose glycans are confined to Asn-402
and Asn-563. The glycosylation sites Asn-171, Asn-332, and
Asn-395 are likely to be occupied by complex glycans. The
glycans at these sites terminated predominantly in galactose or
sialic acid (95.1%), and a small population (4.9%) terminated in
GlcNAc. No glycans were detected on the light chain of IgM by
NP-HPLC (data not shown).
This is the first study of the IgM J chain N-linked glycans
that occupy the single N-linked glycosylation site. The glycans
identified all terminated in galactose or sialic acid, indicating
that the J chain is fully exposed for glycan processing (Table
II). The J chain N-linked glycans of secretory IgA have been
identified by Royle et al. (47) and are occupied by similar glycan
structures identified in IgM, indicating that secretory IgA and
IgM follow the same pathway of polymerization and J chain
attachment.
Based on the proportion of oligomannose identified, we con-
clude that Asn-402 is fully occupied and that Asn-563 has an
occupancy of only 17% in this pooled normal human serum IgM
sample. The proximity of the Asn-563 site to the CH4 domain
has been suggested to make Asn-563 a poor substrate for oli-
gosaccharyltransferase, the enzyme that attaches the
GlcNAc2Man9Glc3 structure to Asn of the N-linked glycosyla-
TABLE II
Pooled normal IgM J chain N-linked glycans
See Table I for details. GU, glucose units.
Structure GU Glycan pool
%
GlcNAc2A2G2 7.12 12.5
FcGlcNAc2A2G2 7.54 2.7
GlcNAc2A2G2S1 7.95 44
FcGlcNAc2A2G2S1 8.34 15
GlcNAc2A2G2S2 8.78 17
FcGlcNAc2A2G2S2 9.14 8
FIG. 4. NP-HPLC exoglycosidase digestion of glycan pool of
pooled normal IgM J chain. The N-linked glycans of the IgM J chain
were analyzed by NP-HPLC before and after sialidase digestion. Per-
centage areas and glucose units (GU) are shown in Table II. All unla-
beled peaks are not glycans.
FIG. 5. Comparison of the NP-HPLC glycan profiles of normal
human IgM and the glycans of IgM eluted from the MBL resin.
The two undigested NP-HPLC profiles are similar. There is a signifi-
cant enrichment (highlighted) of N-linked glycans that terminate in
sugars that could potentially act as ligands for MBL (either mannose or
GlcNAc). f, GlcNAc;, galactose;OO,  linkage; ,  linkage; curved
line, 1–6 linkage; –, 1–4 linkage; , 1–2 linkage.
FIG. 6. MBL binding to IgM preparations. Microtiter plate wells
were coated with TNP-BSA (50 g/well), blocked, and subsequently
saturated with ABS- and BTG-treated anti-TNP-BSA IgM (120 ng/
well). The ABS and BTG treatment cleaves all complex glycans to a
terminal GlcNAc residue to maximize the number of MBL-binding
glycan targets. ABS- and BTG-treated anti-TNP-BSA IgM, large-scale
bulk-purified IgM, and purified IgM that eluted from the MBL resin
were also immobilized directly at 120 ng/well. MBL was incubated at 20
ng/well for 1 h and then sequentially with anti-MBL antiserum and
alkaline phosphatase-conjugated anti-rabbit monoclonal IgG ( chain-
specific) as described by Arnold et al. (32). The assay was developed
with the sensitive 4-methylumbelliferyl phosphate substrate, and the
fluorescence was measured at ex 355 nm and em 460 nm after 1 h.
The bars show mean MBL binding  S.D. EDTA was used in negative
controls, and the EDTA readings were subtracted from the results.
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tion site in the endoplasmic reticulum (55).
Pentameric IgM Model—To form the IgM pentamer (Fig. 7),
the monomers adopt a barrel-like structure rather than a pla-
nar structure. The IgM monomers are sterically unable to form
a planar pentamer, but they can form a planar hexamer struc-
ture (data not shown). The pentameric IgM model suggests
that IgM has two distinct faces, only one of which can bind to
antigen because of the J chain, which projects from the non-
antigen-binding face (Fig. 7b), and because of the barrel-like
monomer arrangement. This would not be true for hexameric
IgM, as the absence of a J chain and the planar arrangement
would allow the Fab domains to flip between the two faces of
the hexamer.
The antigen-binding face of pentameric IgM presents a large
surface of complex glycans (Fig. 7b). IgM may bind to microor-
ganisms via these glycan epitopes as an alternative route of
antigen binding (other than through the Fab V regions). Influ-
enza viruses initiate infection by binding the viral hemagglu-
tinin to sialic acid on the cell surface (56, 57). IgM has 80.7% of
its complex glycan pool terminating in sialic acid, which could
allow IgM to bind to hemagglutinin, neutralizing the virus.
Glycans with one or two terminal galactose residues account
for 83.7% of the complex glycan pool and are a potential ligand
for the asialoglycoprotein receptor, which binds to terminal
galactose residues on serum glycoproteins. Upon binding, the
asialoglycoprotein receptor conveys the ligand for intracellular
degradation and is proposed to be involved in the clearance of
IgA from the blood (58). Once pentameric IgM has bound an-
tigen, these complex glycans on the antigen-binding face (Fig.
7b) appear to become inaccessible (Fig. 6). This is consistent
both with the molecular model and with experimental data as
discussed below. This may slow the clearance of IgM via recep-
tors such as the asialoglycoprotein receptor and promote anti-
gen-bound IgM to activate complement, as with the previously
characterized C1q interaction (31).
MBL Binding to IgM—The glycans from normal total human
serum IgM and those from IgM that eluted from an MBL-
conjugated resin have been compared (Fig. 5 and Table III,
parts A and B). The oligomannose structures that occupy nor-
mal serum IgM Asn-402 are similar in structure to those that
occupy the homologous site in serum IgE (Asn-394) (32). MBL
does not bind the oligomannose structures in serum IgE, as the
additional CH2 hinge domain blocks access to these glycans
(32).
This study has suggested that the occupancy of the normal
human IgM Asn-563 site may be as little as 17%. Therefore,
human serum IgM contains, on average, only one or two oligo-
mannose sugars at the Asn-563 sites in each pentameric IgM
molecule. The low number of potential ligands at this site does
not present a binding surface to which MBL can bind with high
avidity (Fig. 6). Oligomannose structures identified from pooled
normal human serum IgM (23.4% of the glycan pool) were
shown to be increased slightly to 25.3% in IgM eluted from the
MBL resin. There were 43.7% more GlcNAc2Man8 structures
occupying IgM eluted from the MBL-conjugated resin com-
pared with normal serum IgM. GlcNAc2Man8 predominantly
occupies the tail piece Asn-563 (3, 12). IgM that bound to the
MBL resin had 26.4% of the Asn-563 sites occupied (two or
three oligomannose structures at Asn-563 in each pentamer).
We conclude that pooled normal human serum IgM does not
have enough oligomannose occupying Asn-563 for MBL binding
(which needs multiple glycan ligands) to give rise to high avid-
ity binding. The occupancy of the Asn-563 site may be higher in
lower vertebrates, as MBL has been shown to bind murine IgM
(27). Glycan analysis of murine myeloma IgM has shown Asn-
563 to have an occupancy of 44% (four to five accessible oligo-
mannoses/pentamer at the tail piece glycosylation site) and
human-mouse hybridoma IgM to have 42.5% hybrid structures
at Asn-171 (compared with 3.3% in the total glycan pool of
human serum IgM) (54).
In MBL-binding IgM, there was an increase in GlcNAc-
terminating and hybrid structures (Table III, part A) from 7.5
TABLE III
N-Linked glycans that can potentially bind MBL:
comparison of frequency in normal human IgM and
IgM eluted from the MBL column
See the legend to Fig. 3 for explanation of glycan nomenclature.
Part A, the calculated occupancy of Asn-171, Asn-332, and Asn-395
with glycans that have terminal GlcNAc or mannose residues on the
hybrid structures that are potential ligands for MBL. Data are from
both pooled serum IgM and IgM eluted from the MBL resin. Values
were calculated to account for the occupancy of Asn-171, Asn-332, and
Asn-395 ((% glycan in pool % total IgM complex glycan in pool) 100%).
Part B, the calculated occupancy of Asn-402 and Asn-563 with oligom-
annose glycans that occupy only these sites. Data are from both pooled
serum IgM and IgM eluted from the MBL resin (complete occupancy
would produce 40% of the glycan pool as oligomannose structures, two
of five N-linked glycosylation sites. Values were calculated to account
for the occupancy of the two sites. Complete occupancy of both Asn-402
and Asn-563 would total 100% (% oligomannose glycan in pool/40% 
100%).
Occupying Glycan PooledIgM
IgM eluted
from MBL
resin
Increase
% % %
A. Asn-171, Asn-332, GlcNAc2A1 1.0 3.7 208.3
and/or Asn-395 GlcNAc2A2 0.5 1.0 100.0
GlcNAc2A2B 1.6 4.0 150.0
FcGlcNAc2A2 0.3 0.3 0.0
GlcNAc2A3 0.3 0.3 0.0
FcGlcNAc2A2B 0.3 0.4 33.3
GlcNAc2A1Man4G1 0.9 1.9 111.1
GlcNAc2A1Man4G1S1 2.4 3.2 33.3
Total 7.5 14.8 97.3
B. Asn-402 and/ GlcNAc2Man5 14.0 14.3 2.1
Asn-563 GlcNAc2Man6 23.8 21.0 11.8
GlcNAc2Man7 8.0 10.8 35.0
GlcNAc2Man8 10.3 14.8 43.7
GlcNAc2Man9 2.5 2.3 8.0
Total 58.6 63.2 7.8
FIG. 7. Molecular model of the gly-
cosylated IgM pentamer with a glyco-
sylated J chain. The model of pentam-
eric IgM (see “Experimental Procedures”)
shows the non-antigen-binding face (a)
and a 90° rotation (b). The heavy chains
are shown in blue; the light chains are
shown in dark purple; and the J chain is
shown in light purple. The complex gly-
cans (FcGlcNAc2A2BG2S2 attached to
Asn-171, Asn-332, and Asn-395) are
shown in red. The oligomannose glycans
(GlcNAc2Man5 attached to Asn-402 and
GlcNAc2Man8 attached to Asn-563 at
17% occupancy) are shown in green.
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to 14.8% at the complex glycan-occupied sites Asn-171, Asn-
332, and Asn-395. MBL is able to interact with GlcNAc-termi-
nating structures in a similar manner to the interaction that is
seen upon IgG-G0 binding. A small population of hybrid struc-
tures GlcNAc2A1Man4G1 and GlcNAc2A1Man4G1S1 was also
identified; these structures were increased in IgM eluted from
the MBL resin by 111.1 and 33.3%, respectively. Hybrid-type
structures have been shown to occupy only Asn-171 in human-
mouse heterohybridoma human IgM, accounting for 42.5% oc-
cupancy of the site (54). On average, there are four to five
hybrid structures/IgM pentamer.
Pentameric IgM has 10  chains. From the glycan analysis,
each normal human serum IgM contains, on average, 2.3 Glc-
NAc-terminating/hybrid structures on each pentamer (Table
III). As expected, directly immobilized bulk serum IgM showed
poor MBL binding (Fig. 6). MBL is likely to require more than
two ligand glycan structures to bind with a high enough avidity
to be detected in the assays used or to trigger biological func-
tion. Directly bound IgM isolated from the MBL resin bound
MBL much better (Fig. 6). IgM that eluted from the MBL resin
had, on average, 4.4 GlcNAc-terminating/hybrid structures on
each pentamer. The subset of IgM to which MBL bound com-
posed 20% of total serum IgM.
To establish whether these identified oligomannose and Gl-
cNAc-terminating glycans are “presented” or “hidden” upon
antigen binding by IgM, antigen-specific IgM was isolated.
Anti-TNP-BSA IgM was tested both by binding it to the plate
via antigen and by binding it directly (Fig. 6). The IgM prepa-
ration was digested with the exoglycosidases ABS and BTG to
maximize the number of GlcNAc-terminating structures. The
molecular model of pentameric IgM suggests that IgM has two
distinct faces, only one of which can bind antigen. The complex
glycans (including the GlcNAc-terminating structures) that
cover the antigen-binding face of IgM (Fig. 7b) became inacces-
sible once IgM had bound antigen (Fig. 6). As expected, directly
bound anti-TNP-BSA IgM bound MBL, but the antigen-bound
form had very low MBL binding. This confirms, by experimen-
tation, that, upon antigen binding, potential MBL-binding gly-
cans become inaccessible. Antigen-bound IgM pentamers
therefore do not activate complement via the lectin pathway,
but MBL might have a role in the clearance of aggregated IgM.
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